

SUPPLEMENTARY INFORMATION FILE

for

Short flexible peptides linking non-interacting protein domains appear to resist proteolysis by facilitating domain motions that sterically inhibit protease approach

Snehal Waghmare and Purnananda Guptasarma*

Centre for Protein Science, Design and Engineering (CPSDE) and Hyperthermophile Enzyme Hydrolase Research Centre (HEHRC), Department of Biological Sciences, Indian Institute of Science Education and Research (IISER), Mohali, Knowledge City, Sector-81, SAS Nagar, Punjab 140306

Keywords: linker peptide; protein fusion; proteolytic susceptibility; environmental proteases; non-specific proteases; thermostable domains

* Corresponding author Tel: +91 9815417265 Email: guptasarma@iisermohali.ac.in

CONTENTS

Pages 2-3:

Primers used to create Coh2 and the five fusion constructs incorporating five different linkers flanked by Coh2 and BSX

Pages 4-5:

Amino acid sequences of domains and fusion constructs

Page 6:

Mass spectrometric confirmation of the sequence of Coh2 by MALDI-MS

Pages 7-9:

Mass spectrometric confirmation of the sequence of BSX by ESI-Q-TOF MS and MALDI MS

**Primers used to create Coh2, CelF and the five fusion constructs
incorporating five different linkers flanked by Coh2 and BSX**

1. Coh2:

Forward - FP Coh2 Nde1:

ATATATCATATGTCAGACGGTGTGGTAGTAGAAATTGGCAAAG

Reverse - Coh2XhoR:

ATATTACTCGAGTGTTGCATTGCCAACGTTAACACCACCG

2. BSX:

The codon-optimized gene encoding BSX was gotten synthesized commercially

3. CelF:

Forward - CThCelFNhe1F:

ATATATGCTAGCGCGATTCAACTATGGTGAGGC

Reverse - CThCelFXho1R:

TATATTCTCGAGCTGTTTCAGCCGGAATTTTCAATAAG

4. Common forward and reverse primers for the five fusion constructs.

Forward - FP Coh2 Nde1:

ATATATCATATGTCAGACGGTGTGGTAGTAGAAATTGGCAAAG

Reverse - BSXXhoIR:

ATATATCTCGAGAGACTGGAAGTACAGGTTCTCGTCGATGATACGCCAGAACGC

5. Nat-Quarter:

Forward - Coh2BSXlinkF:

GTTGGCAATGCAACACCGACCAAGGGAGCAACAGTTCAGCCGTTTCGCGTGG

Reverse - Coh2BSXlinkR:

TGTTGCTCCCTTGGTCGGTGTTC

6. Nat-Half:

Forward - FP2cohbsxhalf:

AAATACAGCTACGCCGACAAAATCAGCTACGGTTCAGCCCTTCGCGTGG

Reverse - RP2cohlinkhalf:

AGCTGATTTTGTCTGGCGTAGCTGTATTTGTTGGTGTGCTCCCTTGGTCGGTGTTC

7.

Nat-Full:

Forward - FP2cohbsxfull:

CCGACAAACACACCGACAAACACACCCGCAAATACACCAGTTCAGCCGTTTCGCGTGG

Reverse - RP2cohlinkfull:

GTCGGTGTGTTTGTCTGGTACAGATGGCCTGGTGGGGGTAGCCGTAGCTGATTTTGTCTGG

8. *Rigid: (5 amino acids were deleted during cloning)*

Forward - FP2cohbsxrigid:

GCGGCAGCGAAAGAGGCGGCAGCAAAAGAGGCAGCAGCTAAAGTTCAGCCGTTTCGCGTGG

Reverse - RP2cohlinkrigid:

GCTGCCGCCTCTTTCGCTGCCGCCTCTTTCGCTGCCGCCTGCCAACGTTAACACCACC

9. *Flexible: (10 amino acids were deleted during cloning)*

Forward - FP2cohbsxflex:

GGTGGTGGCAGCGGTGGTGGCGGTTCTGGTGGTGGTGGAGTTCAGCCGTTTCGCGTGG

Reverse - RP2cohlinkflex:

GCCACCACCGCTGCCACCACCACCAGAACCGCCACCACCTGAGCCAACGTTAACACCACC

Amino acid sequences of domains and fusion constructs

Note: All genes were cloned in the pET23a vector, between NdeI and XhoI restriction sites, except CelF which was cloned between NheI and XhoI. All genes were expressed in *E.coli* BL21 Star (DE3) pLysS. Further, in all of the sequences shown below:

- The N-terminal methionine and the 6xHis histidine-affinity tag at the C-terminal are shown with green highlighting;
- Linker sequences are shown with grey highlighting;
- Restriction site-derived sequences are shown with red highlighting;
- A Tev protease site that was included in some constructs is shown with yellow highlighting;
- The sequences of Coh2 and BSX are shown without highlighting.
- In the sequence of CelF, the dockerin sequence is shown in cyan.

1. Coh2:

MSDGVVVEIGKVTGSGVTTVEIPVYFRGVPSKGIANCDFVFRYDPNVLEIIGIDPGDIIIDPNPTKSFDTA
IYPDRKIIIVFLFAEDSGTGAYAITKDGVFAKIRATVKSSAPGYITFDEVGGFADNDLVEQKVSFIDGGVN
VGNATLEHHHHHH

2. BSX:

MQPFAWQVASLADRYEESFDIGAAVEPHQLNGRQGKVLKHHYNSIVAENAMKPISLQPEEGVFTWD
GADAIVEFARKNNMNLRFHTLVWHNQVPDWFFLDEEGNPMVEETNEAKRQANKELLERLETHIKTV
VERYKDDVTAWDVVNEVVDDGTPNERGLRESVWYQITGDEYIRVAFETARKYAGEDAKLFINDYNTE
VTPKRDHLYNLVQDLLADGVPIIDGVGHQAHIQIDWPTIDEIRTSMEMFAGLGLDNQVTELDVSLYGW
PRPAFPTYDAIPQERFQAQADRYNQLFELYEELDADLSSVTFWGIADNHTWLDDRAREYNDGVGKDA
PFVFDPNYRVKPAFWRIIDGSEFELRRQACGRTRLEHHHHHH

3. CelF:

MASADFNIGEALQKAIMFYEFQRSGKLPENKRNNWRGDSALNDGADNGLDLTGGWYDAGDHVKFN
LPMAYAVTMLAWSVYESRDAYVQSGQLPYILDNIKWATDYFIKCHPSPNVYYYQVGDGALDHSWWG
PAEVMQMMPRPSFKVDLTNPGSTVVAETAAMAASSIVFKPTDPEYAATLLRHAKELFTFADTTRSDAG
YRAAEGYSSHSFYDELTWASIWLILATGDQSYLDKAESYEPHWERERGTTLISYSWAHCWDNKL
GSLLLAKITGKSYKQCIENHLDYWTGVFNGSRVQYTPKGLAYLDRWGLRYATTQAFLASVYADW
SGCDPAKAAVYKEFAKKQVDYALGSTGRSFVVGFGKNPPRNPHRTAHSSWSALMTEPAECRHILVG
ALVGGPDGSDSYVDRLDDYQCNEVANDYNAGFVGALAKMYEKYGGEPNPFVAFETPGEEFYVEAA
VNAAGPGFVNIKASIINKSGWPARGSDKLSAKYFVDISEAVAKGITLDQITVQSTTNGGAKVSQLLPWD
PDNHIYYVNIDFTGINIFPGGINEYKRDVYFTITAPYGEKNWDNTNDFSQGLEQGFTSKKTEYIPLYDG
NVRVWGKVPDGGSEPDPTTITVGPTPSVTPTSPGIMLGDVNFDGRINSTDYSRLKRYVIKSLEFTDPE
EHQKFIAAADVDGNGRINSTDLVNLNRYILKLIKFPAAEQLEHHHHHH

4. Nat-Quarter or Coh2-Nat-Quarter-BSX:

MSDGVVVEIGKVTGSGVTTVEIPVYFRGVPSKGIANCDFVFRYDPNVLEIIGIDPGDIIIDPNPTKSFDTA
IYPDRKIIIVFLFAEDSGTGAYAITKDGVFAKIRATVKSSAPGYITFDEVGGFADNDLVEQKVSFIDGGVN
VGNATPTKGATVQPFAWQVASLADRYEESFDIGAAVEPHQLNGRQGKVLKHHYNSIVAENAMKPISL
QPEEGVFTWDGADAIVEFARKNNMNLRFHTLVWHNQVPDWFFLDEEGNPMVEETNEAKRQANKELL
LERLETHIKTVVERYKDDVTAWDVVNEVVDDGTPNERGLRESVWYQITGDEYIRVAFETARKYAGED
AKLFINDYNTEVTPKRDHLYNLVQDLLADGVPIIDGVGHQAHIQIDWPTIDEIRTSMEMFAGLGLDNQV
TELDVSLYGWPPRPAFPTYDAIPQERFQAQADRYNQLFELYEELDADLSSVTFWGIADNHTWLDDRAR
EYNDGVGKDAPFVFDPNYRVKPAFWRIIDENLYFQSLEHHHHHH

5. *Nat-Half or Coh2-Nat-Half-BSX:*

MSDGVVVEIGKVTGSGTTEIPVYFRGVPSKGIANCDFVFRYDPNVLEIIGIDPGDIIVDPNPTKSFDTA
IYPDRKIIVFLFAEDSGTGAYAITKDGVF AKIRATVKSSAPGYITFDEVGGFADNDLVEQKVSFIDGGVN
VGNATPTKGATPTNTATPTKSATVQPFQVAVASLADRYEESFDIGAAVEPHQLNGRQGVKHHYNSI
VAENAMKPISLQPEEGVFTWDGADAIVEFARKNNMNLRFHTLVVHNQVPDWFFLDEEGNPMVEETN
EAKRQANKELLERLETHIKTVVERYKDDVTAWDVVNEVVDDGTPNERGLRESVWYQITGDEYIRVA
FETARKYAGEDAKL FINDYNTTEVTPKRDHLYNLVQDLLADGVPIDGVGHQAHIQIDWPTIDEIRTSME
MFAGLGLDNQVTELDVSLYGWPPRPAFPTYDAIPQERFQAQADRYNQLFELYEELDADLSSVTFWGIA
DNHTWLDDRAREYNDGVGKDAPFVFDPNYRVKPAFWRIIDENLYFQSLEHHHHHH

6. *Nat-Full or Coh2-Nat-Full-BSX:*

MSDGVVVEIGKVTGSGTTEIPVYFRGVPSKGIANCDFVFRYDPNVLEIIGIDPGDIIVDPNPTKSFDTA
IYPDRKIIVFLFAEDSGTGAYAITKDGVF AKIRATVKSSAPGYITFDEVGGFADNDLVEQKVSFIDGGVN
VGNATPTKGATPTNTATPTKSATATPTRPSVPTNTPTNPANTPVQPFQVAVASLADRYEESFDIGAAV
EPHQLNGRQGVKHHYNSIVAENAMKPISLQPEEGVFTWDGADAIVEFARKNNMNLRFHTLVVHN
QVPDWFFLDEEGNPMVEETNEAKRQANKELLERLETHIKTVVERYKDDVTAWDVVNEVVDDGTPN
ERGLRESVWYQITGDEYIRVAFETARKYAGEDAKL FINDYNTTEVTPKRDHLYNLVQDLLADGVPIDGV
GHQAHIQIDWPTIDEIRTSMEMFAGLGLDNQVTELDVSLYGWPPRPAFPTYDAIPQERFQAQADRYNQ
LFELYEELDADLSSVTFWGIANHTWLDDRAREYNDGVGKDAPFVFDPNYRVKPAFWRIIDENLYFQS
LEHHHHHH

7. *Flexible or Coh2-Flexible-BSX:*

MSDGVVVEIGKVTGSGTTEIPVYFRGVPSKGIANCDFVFRYDPNVLEIIGIDPGDIIVDPNPTKSFDTA
IYPDRKIIVFLFAEDSGTGAYAITKDGVF AKIRATVKSSAPGYITFDEVGGFADNDLVEQKVSFIDGGVN
VGS GGGGSGGGGVQPFQVAVASLADRYEESFDIGAAVEPHQLNGRQGVKHHYNSIVAENAMKPIS
LQPEEGVFTWDGADAIVEFARKNNMNLRFHTLVVHNQVPDWFFLDEEGNPMVEETNEAKRQANKEL
LLERLETHIKTVVERYKDDVTAWDVVNEVVDDGTPNERGLRESVWYQITGDEYIRVAFETARKYAGE
DAKL FINDYNTTEVTPKRDHLYNLVQDLLADGVPIDGVGHQAHIQIDWPTIDEIRTSMEMFAGLGLDNQ
VTELDVSLYGWPPRPAFPTYDAIPQERFQAQADRYNQLFELYEELDADLSSVTFWGIANHTWLDDRA
REYNDGVGKDAPFVFDPNYRVKPAFWRIIDENLYFQSLEHHHHHH

8. *Rigid or Coh2-Rigid-Quarter-BSX:*

MSDGVVVEIGKVTGSGTTEIPVYFRGVPSKGIANCDFVFRYDPNVLEIIGIDPGDIIVDPNPTKSFDTA
IYPDRKIIVFLFAEDSGTGAYAITKDGVF AKIRATVKSSAPGYITFDEVGGFADNDLVEQKVSFIDGGVN
VGEAAAKEAAAKEAAAKVQPFQVAVASLADRYEESFDIGAAVEPHQLNGRQGVKHHYNSIVAEN
AMKPISLQPEEGVFTWDGADAIVEFARKNNMNLRFHTLVVHNQVPDWFFLDEEGNPMVEETNEAKR
QANKELLERLETHIKTVVERYKDDVTAWDVVNEVVDDGTPNERGLRESVWYQITGDEYIRVAFETA
RKYAGEDAKL FINDYNTTEVTPKRDHLYNLVQDLLADGVPIDGVGHQAHIQIDWPTIDEIRTSMEMFAG
LGLDNQVTELDVSLYGWPPRPAFPTYDAIPQERFQAQADRYNQLFELYEELDADLSSVTFWGIANHT
WLDDRAREYNDGVGKDAPFVFDPNYRVKPAFWRIIDENLYFQSLEHHHHHH

Mass spectrometric confirmation of the sequence of Coh2 by MALDI-MS





Coh2 is 16.54 kDa in size (including its C-terminal 6xHis tag).

Upon digestion by trypsin, it is expected to generate 9 peptides (ignoring missed cleavages).

Of these 9, 4 peptides were observed. These are mentioned in the table along with their sequences.

Mass spectral data for the 4 observed peptides is shown below the table.

Theoretical mass	Observed mass	Sequences of observed peptide masses
636.3351	636.3278	DGVFAK
1141.546	1141.529	GIANCDFVFR
1724.922	1725.93	VTGSVGTTVEIPVYFR
2607.355	2608.366	YDPNVLEIIGIDPGDIIVDPNPTK



Mass spectrometric confirmation of the sequence of BSX by ESI-Q-TOF MS and MALDI MS


BSX is 43.88 kDa in size (including its C-terminal 6xHis tag).

Upon digestion by trypsin, it is expected to generate 69 peptides (with 0 or 1 missed cleavages).


Of these 69 masses, the table (and spectra) below show the masses of 7 representative small peptides using ESI-TOF MS data and 5 representative large peptides using MALDI-TOF data. The sequences are mentioned.

Theoretical mass	Observed mass	Amino acid sequence	Missed cleavages required	MS technique
175.1189	175.0202	R	0	ESI-TOF
246.156	245.0462	AR	0	ESI-TOF
345.2245	344.9760	GLR	0	ESI-TOF
460.2514	460.7669	QANK	0	ESI-TOF
534.2453	534.2521	QACG	0	ESI-TOF
690.3464	690.5695	RQACGR	1	ESI-TOF
772.4563	772.6512	ELLER	0	ESI-TOF
835.4057	836.5156	FQAQADR	0	MALDI-TOF
2085.0399	2088.7859	GLRESVWY QITGDEYIR	1	MALDI-TOF
2288.1081	2289.3584	YAGEDAKLFIN DYNTEVTPK	1	MALDI-TOF
2345.0527	2344.2581	DTVTAWDVVNE VVDDGTPNER	0	MALDI-TOF
3914.8231	3911.0579	FHTLVWHNQVPDWFFL DEEGNPMVEETNEAKR	1	MALDI-TOF


PG_arpana_BS_X_24122015 125 (2.131) Cm (125:135)




PG_17102017_BS_X 13 (0.129) Cm (2:48)




PG_arpana_BS_X_24122015 259 (4.396) Cm (259:288)




PG_arpana_BS_X_24122015 125 (2.131) Cm (125:135)



PG_08012016_ARPANA_BSx 210 (3.567) Cm (200.217)



PG_17102017_BSx1 56 (0.496) Cm (4.90)



PG_281202015_ARPANA_CHYXYL_BAND3_SAMPLE1 85 (1.454) M3 [Ev-974796,It50,En1] (15876.0,3,Pep,Cmp); Cm (85)

TOF MS ES+
3.95e5

